

RNS Number : 7065K  
Diaceutics PLC  
05 November 2024

**Diaceutics - PMx Capital Markets Webinar - Wednesday, 4 December 2024**

**Belfast and London, 5 November 2024 - Diaceutics PLC** (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, will host a virtual Capital Markets Event for analysts and investors to discuss PMx - a suite of data and knowledge driven services built to revolutionise the commercialisation of precision medicines by removing barriers to access and adoption, on **Wednesday, 4 December 2024 at 1400-1530 GMT (0900-1030 ET)**.

The event will include presentations from senior Diaceutics managers and external PMx partners. The purpose of the event will be to give analysts and investors a deeper insight into the DXRX platform and Diaceutics recently launched PMx service which enables Diaceutics' customers to unlock more value from their product commercialisation and also allows Diaceutics a greater share and participation in this value creation.

To register your interest in attending, please use the following link:

[https://us06web.zoom.us/webinar/register/WN\\_aluutKaZQrSEYpRDVdr7bg](https://us06web.zoom.us/webinar/register/WN_aluutKaZQrSEYpRDVdr7bg)

**Enquiries:**

**Diaceutics PLC**

Ryan Keeling, Chief Executive Officer  
Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500  
[investorrelations@diaceutics.com](mailto:investorrelations@diaceutics.com)

**Canaccord Genuity Limited (Nomad & Broker)**

Simon Bridges, Andrew Potts, Harry Rees

Tel: +44 (0)20 7523 8000

**About Diaceutics**

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCDZMGMNMLGDZM